A phase IIa multi-dose study in cirrhotic patients using a tablet formulation to determine the steady-state pharmacokinetics and pharmacodynamics of OCR-002
Phase of Trial: Phase II
Latest Information Update: 23 Aug 2017
At a glance
- Drugs Ornithine phenylacetate (Primary)
- Indications Hepatic encephalopathy
- Focus Pharmacodynamics; Pharmacokinetics
- 23 Aug 2017 According to an Ocera Therapeutics media release, results from this study are expected to be published by the end of 2017.
- 01 Jun 2017 According to an Ocera Therapeutics media release, the first patient has been dosed in this trial.
- 01 Jun 2017 According to an Ocera Therapeutics media release, status changed from planning to recruiting.